Real-world comparative effectiveness of first-line abemaciclib versus palbociclib in HR+/HER2- metastatic breast cancer: A propensity-matched retrospective analysis.

3 , Table 2 , and eTable 8 ) All-cause hospitalizations were slightly less frequent in the abemaciclib group (cumulative probability: 13.8 % vs 20.2 %, with risk ratio: 0.68, 95 % CI: 0.61–0.77), though the difference did not reach statistical significance based on hazard ratio analysis (HR 0.93, 95 % CI 0.81–1.06; P = 0.27).

also in 111,027 other papers